



**Mercy Campus**  
4050 Coon Rapids Blvd  
Coon Rapids, MN 55433  
763-421-8888

**Unity Campus**  
550 Osborne Road  
Fridley, MN 55432  
763-421-2222

**2023**  
**Mercy Campus**  
**Unity Campus**  
**Antimicrobial Susceptibilities**  
**of Major Pathogens**

**Data is also located on the Allina Knowledge Network (AKN):**

- The intent of this document is to provide a preliminary guide to susceptibilities. This information should be used together with the specific susceptibility results of the isolated organism and guidelines from current publications. This report summarizes routinely tested antibiotics. Actual patient reports may selectively exclude some results.
- Results are from inpatients only and include only one isolate per patient.
- Isolates collected from Emergency Department visits are included in the inpatient antibiogram.
- MRSA and VRE surveillance culture isolates are not included.
- All intermediate (I) interpretations are included in the resistant category.
- All organisms identified are held for a period of 7 days after the final results have been reported in case further testing is requested. Blood culture isolates are held for 1 month. Testing of additional antimicrobials is available upon request.
- Additional guidance can be found on the [Allina Health Antibiotic Stewardship Program](#) web page.

**For further information, contact:**

Brenda Katz, MD, Pathologist,  
[Brenda.Katz@allina.com](mailto:Brenda.Katz@allina.com), 612-863-4708

MERCY HOSPITAL-2023 ANTIMICROBIAL SUSCEPTIBILITIES

Gram Negative Bacilli	ISOLATES	Antimicrobials													
		AMPICILLIN	AMPICILLIN/SULBACTAM	CEFZOLIN-UC *	CEFEPIME	CEFTAZIDIME	CEFTRIAZONE	CIPROFLOXACIN	GENTAMICIN	LEVOFLOXACIN	MEROPENEM	NITROFURANTOIN <sup>U</sup>	TOBRAMYCIN	TRIMETHOPRIM/SULFA	
<i>Citrobacter</i> species (all combined)	127				100	84	84	93	96	91	98	91	86	96	94
<i>Enterobacter</i> species (all combined)	156				98	85	80	94	98	90	98	54	82	98	94
<i>Escherichia coli</i>	1854	58	67	88	93	92	92	80	93	76	99	97	96	93	79
<i>Klebsiella aerogenes</i> (formerly <i>Ent. aerogenes</i> )	56				100	82	82	100	100	98	100	28	83	100	100
<i>Klebsiella oxytoca</i>	110		59		96	96	95	96	98	94	99	90	93	97	94
<i>Klebsiella pneumoniae</i>	386		86	92	94	94	94	91	96	88	100	36	94	95	90
<i>Klebsiella variicola</i>	53		94		98	98	98	96	96	88	100	76	96	98	94
<i>Morganella morganii</i>	51		23		100	84	88	80	84	78	98		96	92	78
<i>Proteus mirabilis</i>	216	90	94	97	99	98	98	86	90	86	98		100	91	81
<i>Pseudomonas aeruginosa</i>	333				93	93		88	97	84	94		92	99	
<i>Serratia marcescens</i>	42				100	100	95	92	100	92	100			90	100

\* Cefazolin-UC; the % susceptible can only be ascertained on isolates of *E.coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* from uncomplicated UTIs. The cefazolin threshold for susceptible is <= 2 µg/ml for all other sources and Enterobacterales. The lowest dilution for cefazolin on the Allina FDA cleared automated platform is 4 µg/ml, thus no susceptible results can be determined by this method.

>90% Susceptible
61-89% Susceptible
0-60% Susceptible

GRAM POSITIVE COCCI	ISOLATES	Antimicrobials																						
		AMPICILLIN	AZITHROMYCIN	CEFZOLIN	CEFTRIAZONE	CEFTRIAZONE-MENINGITIS <sup>2</sup>	CEFTRIAZONE-NONMENINGITIS <sup>3</sup>	CLARITHROMYCIN	CLINDAMYCIN	DAPTOMYCIN <sup>4</sup>	DOXYCYCLINE	ERYTHROMYCIN	GENTAMICIN <sup>5</sup>	LEVOFLOXACIN	LINEZOLID	NITROFURANTOIN <sup>U</sup>	OXACILLIN	PENICILLIN	PENICILLIN-IV-MENINGITIS <sup>6</sup>	PENICILLIN-IV-NONMENINGITIS <sup>7</sup>	RIFAMPIN <sup>8</sup>	TRIMETHOPRIM/SULFA	VANCOMYCIN	
<i>Enterococcus faecalis</i>	585	99							71	49			86 <sup>U</sup>	100	99		99							99
<i>Enterococcus faecium</i>	56	35							100 <sup>1</sup>	63			30 <sup>U</sup>	100	40		34							71
<i>Staphylococcus aureus</i>	607		69						80	99	97	58	98	77	100	98	69				99	94	100	100
<i>Staphylococcus Coag Negative</i>	175		48						65	100	94	52	90	72	100	94	48				98	71	100	100
<i>Staphylococcus lugdunensis</i>	38		94						75	100	100	77	100	97	100		94				100	97	100	100
<i>Strep. agalactiae</i> (Strep Group B)	58	100		100					56			53			100		100							100
<i>Strep. dysgalactiae</i>	41	100		100					75			75			100		100							100
<i>Strep. pneumoniae</i> **	47		76		95	100	76										84	100	84		93	100	100	
<i>Strep. pyogenes</i> (Beta StrepGroup A)	31	100		100					87			87			100		100							100

<sup>u</sup> Reported on urine isolates only.

<sup>1</sup> Daptomycin does not have recognized breakpoints for *E. faecium*. Susceptibilities reported in this antibiogram are based on the susceptible dose dependent (SDD) MIC  $\leq 4$   $\mu\text{g/mL}$  using an 8-12 mg/kg daily regimen. Infectious Disease consultation is recommended prior to utilizing daptomycin to cover *E. faecium*.

<sup>2</sup> Ceftriaxone - IV meningitis susceptible MIC  $\leq 0.5$   $\mu\text{g/mL}$ .

<sup>3</sup> Ceftriaxone - IV non-meningitis susceptible MIC  $\leq 1$   $\mu\text{g/mL}$ .

<sup>4</sup> Daptomycin not reported on isolates from respiratory tract.

<sup>5</sup> Gentamicin should not be used as monotherapy for gram positive infections.

<sup>6</sup> Penicillin - Oral and IV meningitis susceptible MIC  $\leq 0.06$   $\mu\text{g/mL}$

<sup>7</sup> Penicillin - IV nonmeningitis susceptible MIC  $\leq 2$   $\mu\text{g/mL}$ .

<sup>8</sup> Rifampin should not be used alone for antimicrobial therapy.

\*\* *S.pneumoniae* isolate distribution by specimen type; 53% blood, 35% respiratory, 2% spinal fluid, 10% other specimen types.

## Links to Related Content

[Allina Health Laboratory](#)

[Organism Groupings of Routinely Test Antimicrobials at Allina Health Laboratory](#)

[Allina Health Antimicrobial Susceptibility Data](#)

[2024 Allina Health Antimicrobial Costs](#)

[Pharmacy Services](#)

[Antimicrobial Stewardship](#)